Fig. 1From: Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trialFlow chart of the SOLTI-1501 VENTANA studyBack to article page